Paul Tudor Jones’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.6M | Sell |
490,000
-54,501
| -10% | -$1.82M | 0.02% | 572 |
|
|
2026
Q1 | $16.4M | Buy |
544,501
+44,501
| +9% | +$1.43M | 0.03% | 507 |
|
|
2025
Q4 | $15.6M | Sell |
500,000
-150,000
| -23% | -$3.7M | 0.03% | 510 |
|
|
2025
Q3 | $13.1M | Hold |
650,000
| – | – | 0.02% | 629 |
|
|
2025
Q2 | $10.9M | Sell |
650,000
-47,457
| -7% | -$766K | 0.02% | 618 |
|
|
2025
Q1 | $10.7M | Buy |
697,457
+247,456
| +55% | +$4.42M | 0.04% | 426 |
|
|
2024
Q4 | $9.92M | Sell |
450,001
-365,000
| -45% | -$6.64M | 0.04% | 362 |
|
|
2024
Q3 | $14.7M | Sell |
815,001
-40,000
| -5% | -$700K | 0.05% | 269 |
|
|
2024
Q2 | $13.9M | Sell |
855,001
-90,048
| -10% | -$1.39M | 0.07% | 272 |
|
|
2024
Q1 | $13.3M | Sell |
945,049
-11,288
| -1% | -$142K | 0.08% | 258 |
|
|
2023
Q4 | $9.98M | Buy |
956,337
+61,836
| +7% | +$577K | 0.08% | 344 |
|
|
2023
Q3 | $9.12M | Buy |
894,501
+208,776
| +30% | +$1.94M | 0.09% | 270 |
|
|
2023
Q2 | $5.16M | Sell |
685,725
-472,253
| -41% | -$3.83M | 0.06% | 412 |
|
|
2023
Q1 | $10.2M | Buy |
1,157,978
+11,859
| +1% | +$117K | 0.16% | 138 |
|
|
2022
Q4 | $10.5M | Buy |
1,146,119
+21,032
| +2% | +$184K | 0.21% | 76 |
|
|
2022
Q3 | $9.08M | Buy |
1,125,087
+10,000
| +0.9% | +$88.4K | 0.2% | 96 |
|
|
2022
Q2 | $8.38M | Buy |
1,115,087
+415,000
| +59% | +$3.62M | 0.22% | 66 |
|
|
2022
Q1 | $6.57M | Buy |
+700,087
| New | +$5.84M | 0.15% | 141 |
|
|
2020
Q4 | – | Sell |
-10,174
| Closed | -$92K | – | 1620 |
|
|
2020
Q3 | $92K | Buy |
+10,174
| New | +$108K | ﹤0.01% | 1190 |
|
|
2020
Q2 | – | Sell |
-10,100
| Closed | -$91K | – | 1413 |
|
|
2020
Q1 | $91K | Sell |
10,100
-496
| -5% | -$5.08K | 0.01% | 935 |
|
|
2019
Q4 | $104K | Buy |
+10,596
| New | +$94.6K | ﹤0.01% | 1050 |
|
|
2016
Q4 | – | Sell |
-5,930
| Closed | -$273K | – | 1605 |
|
|
2016
Q3 | $273K | Buy |
+5,930
| New | +$309K | 0.01% | 1089 |
|
|
2016
Q2 | – | Sell |
-10,782
| Closed | -$577K | – | 1919 |
|
|
2016
Q1 | $577K | Sell |
10,782
-389,218
| -97% | -$22.8M | 0.01% | 852 |
|
|
2015
Q4 | $26.3M | Buy |
400,000
+389,700
| +3,783% | +$24.1M | 0.74% | 23 |
|
|
2015
Q3 | $582K | Sell |
10,300
-389,700
| -97% | -$25.3M | 0.02% | 688 |
|
|
2015
Q2 | $23.6M | Sell |
400,000
-150,000
| -27% | -$9.25M | 0.69% | 28 |
|
|
2015
Q1 | $34.3M | Buy |
+550,000
| New | +$32M | 1.1% | 9 |
|
|
2014
Q2 | – | Sell |
-300,000
| Closed | -$15.9M | – | 1320 |
|
|
2014
Q1 | $15.9M | Buy |
+300,000
| New | +$13.9M | 0.67% | 31 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Paul Tudor Jones's TEVA Position: Q2 2026 in Review
Paul Tudor Jones reduced its Teva Pharmaceuticals (TEVA) stake by 10% in Q2 2026, selling an estimated $1.82M and leaving 490,000 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #572.
Paul Tudor Jones first reported a position in TEVA in Q1 2014 and has held it in 28 quarters since. The position peaked at $34.3M in Q1 2015. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Paul Tudor Jones held 490,000 shares of Teva Pharmaceuticals worth $16.6M as of Q2 2026.
- Paul Tudor Jones sold 54,501 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.82M.
- Teva Pharmaceuticals made up 0.02% of Paul Tudor Jones's portfolio in Q2 2026, its #572 holding.
- Paul Tudor Jones first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 28 quarters since.
- Paul Tudor Jones's Teva Pharmaceuticals position peaked at $34.3M in Q1 2015.
- 671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.